Xylem (XYL) EBITDA (2010 - 2026)

Xylem's EBITDA history runs 17 years deep, the most recent figure standing at $244.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 5.63% year-over-year to $244.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 19.88% YoY), while the FY2025 annual figure was $1.2 billion, up 21.21% from the prior year.
• EBITDA was $244.0 million for Q1 2026 at Xylem, down from $353.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $353.0 million in Q4 2025 to a low of $111.0 million in Q1 2022.
• Historically, EBITDA has averaged $220.6 million across 5 years, with a median of $211.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA fell 18.49% in 2023, then jumped 112.61% in 2024.
• A 5-year view of EBITDA shows it stood at $197.0 million in 2022, then increased by 7.11% to $211.0 million in 2023, then rose by 26.54% to $267.0 million in 2024, then soared by 32.21% to $353.0 million in 2025, then plunged by 30.88% to $244.0 million in 2026.
• The last three EBITDA figures came in at $244.0 million (Q1 2026), $353.0 million (Q4 2025), and $334.0 million (Q3 2025), per Business Quant data.